Clinical trial sponsors said they have adopted new methods and decentralized procedures that may increase diversity and inclusion in future trials.
The changes were prompted by the COVID-19 pandemic, which dissuaded trial participants from attending in-person evaluations and follow-up visits, according to panelists at Fierce JPM Week, a meeting that brought industry experts together to discuss the future of pharma and health care.
“The pivotal moment when we realized something was going to be different was when the number one topic from investigators and field medical staff was the